Cocrystal discovers pan-viral inhibitors targeting hantavirus, bunyavirus, influenza

Cocrystal Pharma announced discovery of novel direct-acting antivirals with pan-viral activity against hantavirus, bunyavirus and influenza, targeting a conserved viral replication enzyme region. The announcement addresses significant unmet medical needs for hantavirus and bunyavirus, which currently lack approved treatments or vaccines.